Last year, consumer-products giant Unilever had a problem. The company wanted to make a meaningful impact in the ultra-crowded category of anti-aging cosmetics, but to do so, it had to come up with entirely new methods for fighting wrinkles. So it turned to Pennington, NJ-based startup BioLeap, which has developed a technology platform that helps scientists assemble new chemical molecules based on the likelihood that they’ll hit specific targets. “A million different things might cause wrinkles,” says BioLeap’s CEO David Pompliano. “We need to figure out those targets and then use a pharmaceutical approach to design molecules that work specifically against them.”